Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurosurgery›Condition·Updated Apr 18, 2026·v1

Meningioma

Meningioma is the most common primary CNS tumor, typically benign but capable of aggressive behavior. Diagnosis is primarily radiological (MRI) and molecular (NF2, TERT). Management involves observation for stable, asymptomatic cases, and surgery or radiation for symptomatic or high-grade lesions.

High Evidence278 references·9,802 words·40 min read·v1
meningiomaneurosurgerybrain tumorWHO GradeNF2radiosurgery

Quick Reference

RxDrug of choiceBevacizumab 10 mg/kg IV every 2 weeks (for refractory high-grade disease/edema)
AltAlternatives177Lu-DOTATATE (PRRT), Everolimus, Somatostatin analogs
⊘AvoidRoutine long-term prophylactic anti-seizure medications in seizure-naive patients
DxTest of choiceMRI Brain with and without Gadolinium
ScKey scoreSimpson Grading System (Extent of Resection)
→When to referSymptomatic mass effect, rapid growth on serial imaging, or WHO Grade 2/3 pathology
Meningiomas are mostly benign but require long-term monitoring; management shifts from observation to surgery or radiation based on symptoms, growth, and molecular grade.
Meningiomas are the most common primary central nervous system (CNS) neoplasms, originating from the arachnoid cap cells of the leptomeninges. While approximately 80-85% are benign (WHO Grade 1), they can cause significant morbidity through mass effect on adjacent neurovascular structures. The clinical course is highly variable, ranging from incidental findings that remain stable for decades to aggressive, malignant variants (WHO Grade 3) with high recurrence rates. Diagnosis relies on characteristic MRI findings, such as the "dural tail sign," and increasingly on molecular stratification, including NF2 status and TERT promoter mutations. Management is highly personalized, utilizing a "wait-and-scan" approach for asymptomatic lesions, maximal safe surgical resection for symptomatic tumors, and stereotactic radiosurgery or fractionated radiotherapy for residual or high-grade disease. Systemic options remain limited but are evolving toward targeted molecular therapies and peptide receptor radionuclide therapy (PRRT).

Overview and Recommendations

Background

  • •Recognize meningiomas as the most prevalent primary intracranial tumor, representing nearly 40% of all CNS neoplasms. They arise from the arachnoid cap cells and are most frequently diagnosed in the sixth and seventh decades of life, with a median age of 66 years.
  • •Identify the strong female predominance, with women affected at roughly twice the rate of men. This disparity is largely attributed to the expression of estrogen and progesterone receptors within the tumor cells, and risk is further modified by exogenous hormone use, such as high-dose progestins or hormone replacement therapy.
  • •Screen for the most significant environmental risk factor: prior exposure to ionizing radiation. Radiation-induced meningiomas (RIMs) often appear 20–30 years after cranial irradiation for childhood malignancies or tinea capitis and are characterized by more aggressive biological behavior, multifocality, and higher histological grades.
  • •Differentiate between the two primary molecular pathways: NF2-mutated and NF2-wildtype. Approximately 50-60% of sporadic cases involve inactivation of the NF2 gene on chromosome 22q, leading to the loss of the tumor suppressor Merlin, while non-NF2 variants often harbor mutations in TRAF7, AKT1, KLF4, or SMO.
  • •Assess for genetic predisposition syndromes in patients presenting with multiple meningiomas or at a young age. is the most common, but other rare syndromes include BAP1 tumor predisposition syndrome (linked to aggressive rhabdoid variants) and Rubinstein-Taybi syndrome.

Evaluation

  • •Suspect meningioma in patients presenting with new-onset focal seizures, progressive headaches, or location-specific neurological deficits. Seizures occur in approximately 30% of symptomatic patients and are often associated with peritumoral brain edema (PTBE).
  • •Perform a detailed cranial nerve survey based on tumor location. For olfactory groove lesions, test for anosmia; for spheno-orbital tumors, evaluate for proptosis and visual field defects; and for cerebellopontine angle lesions, assess for hearing loss or facial nerve weakness.
  • •Order a high-resolution MRI with and without gadolinium as the primary diagnostic modality. Look for a well-circumscribed, dural-based mass that is isointense on T1 and T2 sequences and demonstrates robust, homogeneous enhancement with a characteristic "dural tail sign."
  • •Utilize Fluid-Attenuated Inversion Recovery (FLAIR) sequences to quantify peritumoral brain edema. Significant edema often correlates with higher tumor grade, brain invasion, or specific molecular markers like FOXC1 expression.
  • •Obtain a non-contrast CT scan to evaluate for bone involvement. Meningiomas frequently cause reactive hyperostosis (thickening of the adjacent bone) or may contain internal calcifications (psammoma bodies) in 20-25% of cases.
  • •Consider in complex cases or for recurrence monitoring. Because meningiomas nearly universally overexpress somatostatin receptor 2 (SSTR2), this modality is highly sensitive for delineating tumor margins in the skull base or distinguishing tumor from post-radiation changes.
  • •Apply the 2021 WHO Classification criteria to determine tumor grade. Grade 1 is benign (<4 mitoses/10 HPF); Grade 2 is atypical (4-19 mitoses, brain invasion, or specific histology like clear cell/chordoid); and Grade 3 is anaplastic (≥20 mitoses or frank malignancy).
  • •Identify high-risk molecular markers that override histological appearance. The presence of TERT promoter mutations or CDKN2A/B homozygous deletions automatically classifies a tumor as WHO Grade 3, regardless of the mitotic count.
  • •Use immunohistochemistry (IHC) surrogates for molecular testing when NGS is unavailable. Loss of MTAP expression is a reliable surrogate for CDKN2A deletion, and loss of Merlin expression suggests NF2 alteration.
  • •Evaluate the Ki-67 (MIB-1) proliferation index to estimate recurrence risk. While thresholds vary, a Ki-67 index >5-10% is generally associated with more aggressive growth and a higher likelihood of progression after resection.
  • •Rule out mimics of dural-based lesions, such as (SFT), which is distinguished by STAT6 nuclear expression, or primary dural lymphoma, which typically shows restricted diffusion on MRI.
  • •Assess for venous sinus involvement in parasagittal tumors. Use MR venography (MRV) to determine if the superior sagittal sinus is patent, partially compressed, or completely occluded, as this significantly impacts surgical planning and risk.

Management

  • •Adopt a "wait-and-scan" strategy for asymptomatic, incidental WHO Grade 1 meningiomas. Perform a baseline follow-up MRI at 6 months, then annually if stable; for elderly patients with small lesions, observation is often the definitive management.
  • •Pursue maximal safe surgical resection as the primary treatment for symptomatic or growing tumors. The goal is a Simpson Grade I resection (complete removal of tumor, dural attachment, and involved bone) to minimize the risk of recurrence.
  • •Administer perioperative corticosteroids, such as Dexamethasone 4-10 mg every 6 hours, to manage symptomatic peritumoral edema, tapering as soon as clinically feasible postoperatively.
  • •Initiate anti-seizure medications (ASMs) in patients who have experienced a preoperative seizure. Routine prophylactic ASMs in seizure-naive patients are generally not recommended beyond the immediate postoperative week.
  • •Utilize stereotactic radiosurgery (SRS) as primary treatment for small-to-medium (<3 cm or <8 cc) tumors in surgically high-risk areas like the cavernous sinus. A typical margin dose is 14-16 Gy for Grade 1 lesions.
  • •Recommend fractionated radiotherapy (FSRT) for large tumors or those in close proximity to the optic apparatus. Standard dosing is 50.4-54 Gy delivered in 1.8 Gy fractions to minimize the risk of radiation-induced optic neuropathy.
  • •Mandate adjuvant radiotherapy for all WHO Grade 3 (anaplastic) meningiomas and for WHO Grade 2 (atypical) tumors following subtotal resection (STR). Doses for high-grade disease are typically escalated to 60 Gy.
  • •Consider hypofractionated stereotactic radiosurgery (HSRS), such as 25 Gy in 5 fractions, for medium-sized tumors to provide a high biological dose while sparing adjacent healthy tissue and reducing the risk of radiation-induced edema.
  • •Refer patients with treatment-refractory, high-grade meningiomas for systemic therapy. Bevacizumab 10 mg/kg IV every 2 weeks is the most common first-line systemic agent for managing progressive disease and associated edema.
  • •Evaluate candidates for Peptide Receptor Radionuclide Therapy (PRRT) using (Lutathera) 7.4 GBq every 8 weeks for 4 doses if SSTR2 expression is confirmed on PET imaging and standard options are exhausted.
  • •Explore targeted inhibitors for specific mutations: Vismodegib 150 mg daily for SMO mutations, or Capivasertib 400 mg twice daily for AKT1 mutations, ideally within the context of a clinical trial.
  • •Monitor for long-term complications of radiation, including SMART syndrome (stroke-like migraine attacks after radiation therapy) and radiation-induced cognitive decline, which may manifest years after treatment.
  • •Schedule long-term surveillance imaging. For Grade 1 tumors, annual scans for 5 years then biennial; for Grade 2/3, scans every 3-6 months for the first 2-3 years, as recurrences can occur even a decade after initial treatment.
  • •Refer to neuro-ophthalmology for patients with optic nerve sheath meningiomas or tumors involving the orbit to ensure formal visual field and acuity monitoring.
  • •Discharge patients once they are neurologically stable and have adequate seizure control. Ensure they are aware that any new focal deficit or worsening headache requires immediate re-evaluation.

Board Review — High Yield

  • •Dural Tail Sign — Thickening of the adjacent dura mater on MRI, highly characteristic of meningioma.
  • •Psammoma Bodies — Laminated, whorled calcifications seen histologically in transitional and psammomatous subtypes.
  • •NF2 (Merlin) — The most common genetic driver; loss of chromosome 22q is found in ~60% of cases.
  • •SSTR2 — Somatostatin receptor 2, the biological target for 68Ga-DOTATATE PET imaging and PRRT.
  • •Simpson Grade I — Complete resection of tumor, dura, and bone; associated with the lowest recurrence rate.
  • •TERT Promoter Mutation — A molecular marker that defines WHO Grade 3 (malignant) regardless of histology.
  • •Hyperostosis — Reactive bone thickening adjacent to the tumor, often requiring surgical drilling/resection.
  • •Ionizing Radiation — The only well-established environmental risk factor for meningioma development.

Deep Dive — Evidence Details

References

  1. [1]

    Ateiwi YA, Mahmood R, Wong HJ et al.. “Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 41722869 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  2. [2]

    Pahwa B, Pahwa N, Sheehan JP. “Single session versus hypofractionated stereotactic radiosurgery for large meningiomas (> 8 cc): a systematic review and meta analysis.” Journal of neuro-oncology (2025). PMID: 41291309 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Surgical Management and Techniques, Radiation Therapy and Radiosurgery
  3. [3]

    Sun Z. “Comparative Efficacy of Remimazolam Versus Propofol in Meningioma Surgery with Scalp Nerve Block.” Medical science monitor : international medical journal of experimental and clinical research (2025). PMID: 41076554 ↗

    L1bRCTCited in: Epidemiology and Risk Factors, Prognosis and Recurrence Patterns
  4. [4]

    Singh R, Koempel A, French B et al.. “Improved progression-free survival following dose-escalated vs. standard dose post-operative radiation therapy for high-risk meningiomas: An International Multicenter Individual Patient Level Meta-Analysis (FIRESTORM).” International journal of radiation oncology, biology, physics (2026). PMID: 41956162 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  5. [5]

    Krzemińska A, Więcław J, Koźba-Gosztyła M et al.. “Radiation-Induced Meningiomas: Systematic Review with Pooled Case Analysis and Case Series of Long Latency, Aggressive Behavior, and Clinical Outcomes.” Journal of clinical medicine (2026). PMID: 41899280 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  6. [6]

    Falcao V, Rego LHRM, Rodrigues PB et al.. “Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis.” Journal of neuro-oncology (2026). PMID: 41721900 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  7. [7]

    Alare K, Afolabi SA, Adetunji B et al.. “Trends of hospital-based reporting of intracranial neoplasms in Nigeria from 1960 to 2024: A systematic review and pooled analysis of literatures.” Neuro-oncology advances (2025). PMID: 41323960 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  8. [8]

    Byun YH, Han M, Nam SM et al.. “Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.” Acta neurochirurgica (2025). PMID: 41324743 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Classification and WHO Grading, Immunohistochemistry and Molecular Markers, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  9. [9]

    Mahjari A, Alyazidi A, El-Sayed K et al.. “Traumatic Brain Injury and Risk of Intracranial Meningioma : A Systematic Review and Meta-Analysis.” Journal of Korean Neurosurgical Society (2026). PMID: 41921582 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  10. [10]

    Tettamanti G, Shu X, Mogensen H et al.. “Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study.” Neuro-oncology (2026). PMID: 41056434 ↗

    L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Prognosis and Recurrence Patterns
  11. [11]

    Ye E, Hines D, Reddy SB et al.. “Pediatric meningioma and seizures: a single-center cohort study.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2026). PMID: 41526775 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns, Guidelines and Resources
  12. [12]

    Fadhil Hashim A, Karimi A, Ghanbari S et al.. “Ambient Air Pollution and Risk of Brain Tumors: A Systematic Review and Meta-Analysis.” Asian Pacific journal of cancer prevention : APJCP (2026). PMID: 41660899 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  13. [13]

    Smerdi D, Anastasopoulos L, Charalampopoulou E et al.. “Coexistence of histologically distinct intracranial tumors: Case series, literature review, and meta-analysis.” Surgical neurology international (2026). PMID: 41952732 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  14. [14]

    Almeida ND, Sinha S, Fang M et al.. “Radiation-induced meningiomas: A systematic review and meta-analysis of 927 meningiomas.” Surgical neurology international (2026). PMID: 41660311 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  15. [15]

    Passeri T, Alcântara T, Fava A et al.. “Chopsticks mononostril approach with sphenoid sinus cranialization and septal mucosa suturing: a new minimally invasive concept and closure technique for endoscopic endonasal approaches.” Journal of neurosurgery (2026). PMID: 41825064 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  16. [16]

    Zeng W, Jedwood C, Chung R et al.. “Associations of surgical menopause and hormone replacement therapy with meningioma development.” Journal of neuro-oncology (2026). PMID: 41817782 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  17. [17]

    Edwards E, Tsai K, Pappu S et al.. “Incidence of meningioma in women with a history of combined oral contraceptive pill use and polycystic ovary syndrome.” Women's health (London, England) (2026). PMID: 41699937 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  18. [18]

    Ko SW, Won YD, Ha BJ et al.. “Optimal α/β Ratio for Biologically Effective Dose-Based Prediction of Radiation-Induced Peritumoral Brain Edema in Meningioma.” Cancers (2026). PMID: 41681920 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  19. [19]

    Leistner T, Terrapon APR, Hostettler IC et al.. “Adverse events in meningioma surgery classified using the therapy-disability-neurology (TDN) grading system.” Journal of neuro-oncology (2025). PMID: 41400878 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Surgical Management and Techniques
  20. [20]

    Naert L, Stroobants S, Vandamme T et al.. “The prevalence and clinical significance of 68Ga-DOTANOC incidentaloma.” Endocrine-related cancer (2026). PMID: 41395644 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  21. [21]

    Bowers DC, Cooney T, Chen Y et al.. “Subsequent Meningiomas Among Survivors of Childhood Cancer.” JAMA network open (2025). PMID: 41379444 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  22. [22]

    Holmgren K, Fletcher-Sandersjöö A, Sæmundsson B et al.. “Cranioplasty after surgical site infection in brain tumor patients: insights from a 15-year Swedish multicenter study.” Journal of neurosurgery (2026). PMID: 41349038 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  23. [23]

    Jiang C, McWilliams T, Berger M et al.. “Periventricular radionecrosis after conventionally fractionated radiation for low grade meningiomas.” Radiation oncology (London, England) (2025). PMID: 41291917 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  24. [24]

    Islim AI, Millward CP, Zakaria R et al.. “A Clinical Tool to Identify Incidental Meningioma for Early Outpatient Management.” JAMA oncology (2026). PMID: 41264316 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Diagnostic Imaging and Radiology, Special Populations: Pediatric and Genetic Syndromes
  25. [25]

    Albarracín Cárdenas CI, Caballero Rojas H, Ochoa Vera ME et al.. “Survival of nervous system tumors in a Colombian population cancer registry.” Journal of neuro-oncology (2025). PMID: 41247425 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  26. [26]

    Lenga P, Scherer M, Dao Trong P et al.. “Sex-specific disparities in postoperative adverse events following intracranial tumor surgery: insights from a tertiary neurosurgical center.” Acta neurochirurgica (2025). PMID: 41231356 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  27. [27]

    Khalili BF, Chojnacki MR, Dixit K et al.. “Surgical Treatment of Brain Tumor-Related Epilepsy: Current and Emerging Strategies.” Cancers (2025). PMID: 41228332 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  28. [28]

    Tas KT, Höft FS, Agolli L et al.. “Long-term outcomes and toxicity of radiotherapy for WHO Grade II and III meningiomas: a retrospective analysis of 98 patients.” Journal of neuro-oncology (2025). PMID: 41134468 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Classification and WHO Grading, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Radiation Therapy and Radiosurgery
  29. [29]

    Rai P, Mehta T, Kumar SS et al.. “Metastatic Meningioma: Neuroradiologic and Molecular Imaging Perspectives.” Radiology. Imaging cancer (2025). PMID: 41104976 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Immunohistochemistry and Molecular Markers, Diagnostic Imaging and Radiology, Systemic Therapy and Emerging Treatments
  30. [30]

    Price M, Ballard CAP, Benedetti JR et al.. “CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022.” Neuro-oncology (2025). PMID: 41092086 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  31. [31]

    Sahm F, Bertero L, Brandner S et al.. “European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.” Neuro-oncology (2025). PMID: 39577862 ↗

    L1cGUIDELINECited in: Etiology and Molecular Pathogenesis, Systemic Therapy and Emerging Treatments, Special Populations: Pediatric and Genetic Syndromes, Guidelines and Resources
  32. [32]

    Chen A, Hart SL, Lannon M et al.. “Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.” Journal of neuropathology and experimental neurology (2025). PMID: 39740655 ↗

    L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis
  33. [33]

    Huo X, Wang L, Ma J et al.. “Bibliometric analysis of publication trends in meningioma research (1992 - 2023).” Neurosurgical review (2025). PMID: 40779080 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Immunohistochemistry and Molecular Markers, Systemic Therapy and Emerging Treatments, Special Populations: Pediatric and Genetic Syndromes
  34. [34]

    Lotsch C, Warta R, Herold-Mende C. “The Molecular and Immunological Landscape of Meningiomas.” International journal of molecular sciences (2024). PMID: 39273576 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Systemic Therapy and Emerging Treatments
  35. [35]

    Hsieh AL, Bi WL, Ramesh V et al.. “Evolving concepts in meningioma management in the era of genomics.” Cancer (2024). PMID: 38753473 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes
  36. [36]

    Caccese M, Busato F, Guerriero A et al.. “The role of radiation therapy and systemic treatments in meningioma: The present and the future.” Cancer medicine (2023). PMID: 37366279 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis
  37. [37]

    Cumpston EC, Rhodes SD, Yates CW. “Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.” Current oncology reports (2023). PMID: 36933171 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis
  38. [38]

    Wu JP, Yu L, Mu CP et al.. “A Rare Instance of Rosai-dorfman Disease With Mimicking Meningioma.” The Journal of craniofacial surgery (2025). PMID: 39902913 ↗

    L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis, Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  39. [39]

    Cheng J, Guo C. “Primary pulmonary meningioma: a case report and literature review.” Journal of cardiothoracic surgery (2025). PMID: 39773541 ↗

    L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis, Systemic Therapy and Emerging Treatments
  40. [40]

    Shimasaki T, Akutsu N, Koyama J et al.. “Pediatric intraparenchymal meningioma in the basal ganglia treated with gross total resection: a case report and review of the literature.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2023). PMID: 37369950 ↗

    L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis
  41. [41]

    Trabzonlu L, Martinez-Lage M, Deschler D et al.. “FNA of Meningioma with Rhabdoid Features Presenting as a Lateral Neck Mass.” Head and neck pathology (2024). PMID: 38658429 ↗

    L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis
  42. [42]

    Sadagopan NS, Nandoliya KR, Youngblood MW et al.. “A novel BRAF::PTPRN2 fusion in meningioma: a case report.” Acta neuropathologica communications (2023). PMID: 38066633 ↗

    L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis
  43. [43]

    Mansour MA, Mostafa HN, Elsamman AK. “Decoding Meningioangiomatosis: A Century of Insights into Molecular Mechanisms, Clinical Dilemmas, and Therapeutic Innovations.” World neurosurgery (2026). PMID: 41325933 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Surgical Management and Techniques, Special Populations: Pediatric and Genetic Syndromes
  44. [44]

    Graillon T, Tabouret E, Salgues B et al.. “Innovative treatments for meningiomas.” Revue neurologique (2023). PMID: 36959063 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis
  45. [45]

    Sakaguchi M, Horie M, Ito Y et al.. “Clinicopathological significance of loss of Y chromosome in male meningiomas.” The Journal of pathology (2026). PMID: 41715910 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Classification and WHO Grading, Prognosis and Recurrence Patterns, Special Populations: Pediatric and Genetic Syndromes
  46. [46]

    Zhang L, Ye Y, Gu W et al.. “KMT2C Loss Promotes NF2-Wildtype Meningioma Progression and Ferroptosis Sensitivity via Epigenetic Repression of Hippo Signaling.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41642951 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes
  47. [47]

    Ohara K, Miyawaki S, Teranishi Y et al.. “Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.” Acta neuropathologica communications (2025). PMID: 41250239 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Immunohistochemistry and Molecular Markers
  48. [48]

    Drabent P, Touat M, Benusiglio PR et al.. “A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology.” Neuropathology and applied neurobiology (2025). PMID: 41024725 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  49. [49]

    Alkhatib M, Hua L, Beyer F et al.. “Molecular landscape and clinical correlates of olfactory groove meningiomas: a multi-institutional study.” Journal of neurosurgery (2025). PMID: 40911921 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Classification and WHO Grading
  50. [50]

    Kashiwagi-Hakozaki M, Ikemura M, Miyawaki S et al.. “Merlin immunohistochemistry is a reliable surrogate marker for NF2 gene alterations in meningioma.” Histopathology (2025). PMID: 40815185 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Classification and WHO Grading, Gross and Microscopic Features, Special Populations: Pediatric and Genetic Syndromes
  51. [51]

    Shah M, Akther Y, Adams CL et al.. “Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.” EBioMedicine (2025). PMID: 40562609 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes
  52. [52]

    Tollefsen SE, Meta R, Solheim O et al.. “Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.” Journal of neuropathology and experimental neurology (2025). PMID: 40447281 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Gross and Microscopic Features, Special Populations: Pediatric and Genetic Syndromes
  53. [53]

    Li H, Huang Z, Wang Y et al.. “Clinicopathologic and Genomic Characteristics of Minute Pulmonary Meningothelial-like Nodules.” Laboratory investigation; a journal of technical methods and pathology (2025). PMID: 40311876 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes
  54. [54]

    Sievers P, Arora S, Hielscher T et al.. “Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.” Neuro-oncology (2025). PMID: 40249111 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  55. [55]

    Dedhia M, Devarajan A, Rao A et al.. “Somatic AKT1 Mutations May Confer Increased Risk of Preoperative Seizures in Meningiomas.” Neurosurgery (2025). PMID: 40214250 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  56. [56]

    Tang H, Xu F, Sun D et al.. “Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.” CNS neuroscience & therapeutics (2025). PMID: 39996452 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  57. [57]

    Mair MJ, Hartenbach S, Tomasich E et al.. “Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.” European journal of nuclear medicine and molecular imaging (2025). PMID: 39969538 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  58. [58]

    Zhang N, Shen X, Yu Y et al.. “Lead exposure promotes NF2-wildtype meningioma cell proliferation through the Merlin-Hippo signaling pathway.” Environmental health and preventive medicine (2025). PMID: 39894505 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  59. [59]

    Ren L, Deng J, Wakimoto H et al.. “Clinical and molecular characteristics and long-term outcomes of pediatric intracranial meningiomas: a comprehensive analysis from a single neurosurgical center.” Acta neuropathologica communications (2025). PMID: 39856730 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  60. [60]

    Devarajan A, Seah C, Zhang JY et al.. “A four-hit mechanism is sufficient for meningioma development.” Journal of neuro-oncology (2025). PMID: 39586894 ↗

    L5OTHERCited in: Etiology and Molecular Pathogenesis
  61. [61]

    Cordia QCF, Dijkstra BM, Groen RJM. “The dural tail in intracranial meningioma: Heads up or tail down? A systematic review of the literature.” Neurosurgical review (2025). PMID: 40542302 ↗

    L2aSR_OBSCited in: Classification and WHO Grading
  62. [62]

    Dono A, Pichardo-Rojas D, Mendoza Mora L et al.. “MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.” Journal of neuropathology and experimental neurology (2025). PMID: 40249413 ↗

    L2aSR_OBSCited in: Classification and WHO Grading, Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  63. [63]

    Khaleghi M, Tao M, Dyess G et al.. “Comparative analysis of facial nerve outcomes in petroclival versus posterior petrous meningioma surgery: A systematic review and meta-analysis of 2884 patients.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40578007 ↗

    L2aSR_OBSCited in: Classification and WHO Grading
  64. [64]

    Suematsu Y, Nagoshi N, Okubo T et al.. “Comparison of surgical and clinical outcomes between ventral and dorsal/lateral thoracic intradural extramedullary meningiomas: a retrospective study.” Spinal cord (2026). PMID: 41145830 ↗

    L2bCOHORTCited in: Classification and WHO Grading, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns
  65. [65]

    Gaggero G, Pesaresi A, Giunti D et al.. “PD-L1 expression pattern as predictive factor of biological behaviour in intracranial meningiomas: A single-center retrospective study.” European journal of clinical investigation (2026). PMID: 40990537 ↗

    L2bCOHORTCited in: Classification and WHO Grading, Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  66. [66]

    Lee CC, Wujanto C, Handa P et al.. “The value of radiotherapy in patients with recurrent atypical meningioma: an update.” Expert review of neurotherapeutics (2025). PMID: 40944339 ↗

    L5REVIEW_NARRATIVECited in: Classification and WHO Grading
  67. [67]

    He T, Zhang Z, Wang X. “A huge cerebral parenchymal meningioma in sylvian fissure: case report and literature review.” BMC neurology (2025). PMID: 40188049 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading, Clinical Presentation and Neurological Manifestations
  68. [68]

    Eghtedari M, Mitchell WG, Hardy TG. “Atypical Optic Nerve Sheath Meningioma With Postbiopsy Ophthalmic Artery Occlusion.” Ophthalmic plastic and reconstructive surgery (Unknown). PMID: 40153799 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading, Gross and Microscopic Features
  69. [69]

    Aman RA, Amelia R, Arqursoy H et al.. “Insights on Survival and Recurrence After Surgery in Malignant Meningiomas: A Systematic Review and Meta-Analysis.” Asian Pacific journal of cancer prevention : APJCP (2025). PMID: 41312917 ↗

    L2aSR_OBSCited in: Classification and WHO Grading, Immunohistochemistry and Molecular Markers, Surgical Management and Techniques, Radiation Therapy and Radiosurgery, Systemic Therapy and Emerging Treatments, Prognosis and Recurrence Patterns
  70. [70]

    Caldonazzi N, Hernandez Gamero G, Mafficini A et al.. “Relevance of next-generation sequencing in the differential diagnosis of meningeal mesenchymal tumors: primary meningeal dedifferentiated chondrosarcoma of the cavernous sinus.” Pathologica (2025). PMID: 41954345 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading
  71. [71]

    D'Andrea M, Costanzo R, Fuschillo D et al.. “Comparative outcomes of giant versus non-giant anterior clinoidal meningiomas: A single-center case series with extended follow-up.” Neurosurgical review (2025). PMID: 41326908 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading, Clinical Presentation and Neurological Manifestations, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  72. [72]

    Shao X, Xu Z, Liu P et al.. “TERT promoter C250T mutation in a recurrent cervical chordoid meningioma: a unique case report.” World journal of surgical oncology (2025). PMID: 41013491 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading, Immunohistochemistry and Molecular Markers
  73. [73]

    Fujiwara K, Shibao S, Sasao R et al.. “Endoscopic-assisted contralateral interhemispheric transfalcine keyhole approach for falcine meningioma: How I do it.” Acta neurochirurgica (2025). PMID: 40126699 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading
  74. [74]

    Ye E, Gupta A, Lyons AT et al.. “Pediatric meningioma and seizures: A scoping review.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2025). PMID: 40637916 ↗

    L5REVIEW_NARRATIVECited in: Classification and WHO Grading, Clinical Presentation and Neurological Manifestations
  75. [75]

    Deng D, Yang Y, Cheng B et al.. “Middle ear lymphoepithelioma-like carcinoma with cerebellopontine angle invasion misdiagnosed as meningioma: A case report and literature review.” The Journal of international medical research (2026). PMID: 41986889 ↗

    L4CASE_REPORTCited in: Classification and WHO Grading, Surgical Management and Techniques
  76. [76]

    Fukami S, Akimoto J, Nagai K et al.. “Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes.” Journal of neuro-oncology (2026). PMID: 41917547 ↗

    L5OTHERCited in: Classification and WHO Grading, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  77. [77]

    Thompson E, Indelicato DJ, Brisson RJ et al.. “Outcomes Following Proton Radiation for Pediatric Meningiomas.” Pediatric blood & cancer (2026). PMID: 41496666 ↗

    L5OTHERCited in: Classification and WHO Grading, Radiation Therapy and Radiosurgery, Prognosis and Recurrence Patterns, Special Populations: Pediatric and Genetic Syndromes
  78. [78]

    Wang M, Ding M, Xia W et al.. “Microsurgical resection of skull base meningioma involving internal carotid artery: The power of blood flow reconstruction.” Neurosurgical review (2025). PMID: 41369922 ↗

    L5OTHERCited in: Classification and WHO Grading, Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  79. [79]

    Jhandi S, Goold E, Jensen RL. “Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up.” Journal of neuro-oncology (2025). PMID: 41094320 ↗

    L5OTHERCited in: Classification and WHO Grading
  80. [80]

    Luo XX, Peng B, Wang JH et al.. “Identification of a Novel Oxidative Stress-Based Molecular Classification and Treatment Vulnerabilities in WHO Grade 2/3 Meningiomas.” Oncology research (2025). PMID: 41050085 ↗

    L5OTHERCited in: Classification and WHO Grading, Guidelines and Resources
  81. [81]

    Diebold M, Becker L, Demerath T et al.. “Non-invasive Prediction of Meningioma Tumor Grade by Quantification of Shape-based Radiomics Features and Surface Regularity.” Clinical neuroradiology (2026). PMID: 40960507 ↗

    L5OTHERCited in: Classification and WHO Grading
  82. [82]

    Haddad AF, Ramesh R, Zakimi N et al.. “Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.” Neuro-oncology (2025). PMID: 40916651 ↗

    L5OTHERCited in: Classification and WHO Grading
  83. [83]

    Wei CZ, Niranjan A, Deng H et al.. “The 35-Year Evolution of Stereotactic Radiosurgery for Meningiomas.” Neurosurgery (2026). PMID: 40844288 ↗

    L5OTHERCited in: Classification and WHO Grading, Radiation Therapy and Radiosurgery
  84. [84]

    Saadh MJ, Albadr RJ, Sur D et al.. “Reproducible meningioma grading across multi-center MRI protocols via hybrid radiomic and deep learning features.” Neuroradiology (2025). PMID: 40824403 ↗

    L5OTHERCited in: Classification and WHO Grading
  85. [85]

    Peng TC, Hsieh MH, Lin CF et al.. “Repeated stereotactic radiosurgery for high grade meningioma.” Journal of neuro-oncology (2025). PMID: 40802120 ↗

    L5OTHERCited in: Classification and WHO Grading, Radiation Therapy and Radiosurgery
  86. [86]

    Gomes FC, Ferreira MY, Pereira MAOM et al.. “Fully endoscopic approach to cerebellopontine angle tumors: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 41251909 ↗

    L2aSR_OBSCited in: Gross and Microscopic Features, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  87. [87]

    Ferreira MY, Scarramal JPL, Cheidde L et al.. “Treatment and outcomes of concomitant parasellar meningiomas and anterior circulation aneurysms: a systematic review and perspective in the endovascular era.” Neurosurgical review (2025). PMID: 40338346 ↗

    L2aSR_OBSCited in: Gross and Microscopic Features, Clinical Presentation and Neurological Manifestations
  88. [88]

    Huang W, Liao J, Liu T et al.. “Unilateral biportal endoscopy for the treatment of high-grade thoracic spinal meningioma: a case report and review of the literature.” Journal of cancer research and clinical oncology (2025). PMID: 41071365 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features
  89. [89]

    Di Lorenzo S, Farese S, Balbo C et al.. “The First Case Report of a Solitary Pulmonary Metastasis of a Transitional Meningioma and Literature Review.” International journal of molecular sciences (2025). PMID: 40725113 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features
  90. [90]

    Jung A, Brodhun M, Lemmer A et al.. “Meningioma and Cerebral Spindle Cell Sarcoma as Two Different Metachronous Tumor Entities Secondary to Medulloblastoma Treatment in Childhood: Case Report and Review of the Literature.” Journal of neurological surgery. Part A, Central European neurosurgery (2026). PMID: 40404129 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features
  91. [91]

    Tomakin F, Engin R, Şener H et al.. “Impact of BrainLab VectorVision Infrared-Based Neuronavigation on Surgical Outcomes in Intracranial Meningioma Patients: A Retrospective Study.” Medical science monitor : international medical journal of experimental and clinical research (2024). PMID: 38990791 ↗

    L2bCOHORTCited in: Gross and Microscopic Features
  92. [92]

    Li Y, Li Y, Liu J et al.. “Concurrent spinal meningioma and giant invasive schwannoma without neurofibromatosis in children: A case report and literature review.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2024). PMID: 38349526 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features
  93. [93]

    Aung TM, Ngamjarus C, Proungvitaya T et al.. “Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.” PloS one (2024). PMID: 38758750 ↗

    L2aSR_OBSCited in: Gross and Microscopic Features
  94. [94]

    Shi Z, Yang B, Shen C. “Important role of endoscope in tuberculum sellae meningioma resection via supraorbital keyhole approach.” Acta neurochirurgica (2025). PMID: 40047981 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features
  95. [95]

    Peters RK. “Vestibular epilepsy associated with a temporoparietal lobe meningioma in a cat.” Journal of veterinary internal medicine (2025). PMID: 39890586 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features, Clinical Presentation and Neurological Manifestations
  96. [96]

    d'Avella E, Somma T, Fabozzi GL et al.. “Endoscopic transorbital and transcranial multiportal resection of a sphenoorbital meningiomas with custom bone 3D printing reconstruction: Case report.” Head & neck (2024). PMID: 37994687 ↗

    L4CASE_REPORTCited in: Gross and Microscopic Features
  97. [97]

    Pietrantoni A, Barresi V. “The prognostic value of H3 K27me3 in meningiomas: A review on current evidence and methodological challenges.” Histology and histopathology (2025). PMID: 39663868 ↗

    L5REVIEW_NARRATIVECited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  98. [98]

    Tollefsen SE, Jarmund AH, Solheim O et al.. “Human Meningiomas Reveal No Evidence of Neuroendocrine Differentiation.” APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2026). PMID: 41769706 ↗

    L5OTHERCited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  99. [99]

    Iff I, Gutt-Will M, Maragkou T et al.. “The Diagnostic Value of Confocal Laser Endomicroscopy in Brain Tumours When Performed by Blinded, Untrained Neuropathologists.” Neuropathology and applied neurobiology (2026). PMID: 41545022 ↗

    L5OTHERCited in: Gross and Microscopic Features, Surgical Management and Techniques
  100. [100]

    Broechner A, Maier AD, Mirian C et al.. “Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.” Journal of neuropathology and experimental neurology (2026). PMID: 41267161 ↗

    L5OTHERCited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  101. [101]

    Murayi R, El-Abtah M, Ejikeme T et al.. “Validation of an immunohistochemistry-based molecular group stratification of intracranial meningiomas.” Journal of neuropathology and experimental neurology (2026). PMID: 41093285 ↗

    L5OTHERCited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers
  102. [102]

    Maeoka R, Matsuda R, Nakazawa T et al.. “Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025). PMID: 40300389 ↗

    L5OTHERCited in: Gross and Microscopic Features
  103. [103]

    Hemmer S, Hui X, Draeger J et al.. “AlkaPhos: a novel fluorescent probe as a potential point-of-care diagnostic tool to estimate recurrence risk of meningiomas.” Neurosurgical review (2025). PMID: 39775316 ↗

    L5OTHERCited in: Gross and Microscopic Features
  104. [104]

    Sharma S, Shamjetsabam ND, Chauhan K et al.. “Quantitative tissue analysis reveals AK2, COL1A1, and PLG protein signatures: targeted therapeutics for meningioma.” International journal of surgery (London, England) (2024). PMID: 39288025 ↗

    L5OTHERCited in: Gross and Microscopic Features
  105. [105]

    Bargiela-Cuevas S, Marin M, Gabaldon-Ojeda M et al.. “Histone Acetyl Transferase 1 Is Overexpressed in Poor Prognosis, High-grade Meningeal and Glial Brain Cancers: Immunohistochemical and Aptahistochemical Study.” The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (2024). PMID: 39180315 ↗

    L5OTHERCited in: Gross and Microscopic Features
  106. [106]

    Ieni A, Pizzimenti C, Fiorentino V et al.. “Immunohistochemical Profile of p62/SQSTM1/Sequestosome-1 in Human Low- and High-Grade Intracranial Meningiomas.” Analytical cellular pathology (Amsterdam) (2024). PMID: 39131899 ↗

    L5OTHERCited in: Gross and Microscopic Features
  107. [107]

    Thirunavu V, Drumm M, McCord M et al.. “Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis.” Journal of neurosurgery (2024). PMID: 38968615 ↗

    L5OTHERCited in: Gross and Microscopic Features
  108. [108]

    Morisako H, Sasaki T, Ikegami M et al.. “Purely endoscopic subtemporal keyhole anterior transpetrosal approach to access the petrous apex region: surgical techniques and early results.” Journal of neurosurgery (2024). PMID: 38579340 ↗

    L5OTHERCited in: Gross and Microscopic Features
  109. [109]

    Tauziède-Espariat A, Masliah-Planchon J, Sievers P et al.. “A comprehensive histomolecular characterization of meningioangiomatosis: Further evidence for a precursor neoplastic lesion.” Brain pathology (Zurich, Switzerland) (2024). PMID: 38565263 ↗

    L5OTHERCited in: Gross and Microscopic Features
  110. [110]

    Helal A, Hammam E, Ovenden CD et al.. “A systematic review of radiological prediction of ki 67 proliferation index of meningioma.” Neurosurgical review (2024). PMID: 39621118 ↗

    L2aSR_OBSCited in: Immunohistochemistry and Molecular Markers
  111. [111]

    S S, Pendem S, K P et al.. “Machine learning based radiomics approach for outcome prediction of meningioma - a systematic review.” F1000Research (2025). PMID: 40206662 ↗

    L2aSR_OBSCited in: Immunohistochemistry and Molecular Markers
  112. [112]

    Broomand Lomer N, Khalaj F, Ghorani H et al.. “MRI-derived radiomics models for prediction of Ki-67 index status in meningioma: a systematic review and meta-analysis.” Clinical imaging (2025). PMID: 39986203 ↗

    L2aSR_OBSCited in: Immunohistochemistry and Molecular Markers
  113. [113]

    Brastianos PK, Dooley K, Geyer S et al.. “Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.” Nature medicine (2026). PMID: 41545592 ↗

    L2bTRIAL_NONRANDOMCited in: Immunohistochemistry and Molecular Markers, Prognosis and Recurrence Patterns, Special Populations: Pediatric and Genetic Syndromes
  114. [114]

    Aktoklu M, Bıyık MO, Topsakal AS et al.. “Myeloid sarcoma of the skull base: a brief review of the literature and a rare case confused radiologically with end plaque meningioma.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41454030 ↗

    L4CASE_REPORTCited in: Immunohistochemistry and Molecular Markers, Diagnostic Imaging and Radiology, Surgical Management and Techniques
  115. [115]

    Teng H, Yu J, Pang Y et al.. “Long-term recurrence risk and temporal dynamics after resection of intracranial meningiomas: A multicenter cohort study with up to 15 years of follow-up.” Cancer (2025). PMID: 41319250 ↗

    L2bCOHORTCited in: Immunohistochemistry and Molecular Markers, Surgical Management and Techniques, Radiation Therapy and Radiosurgery
  116. [116]

    Gui C, Wang JZ, Patil V et al.. “Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study.” The Lancet. Oncology (2025). PMID: 40907516 ↗

    L2bCOHORTCited in: Immunohistochemistry and Molecular Markers
  117. [117]

    Shukla IY, Ebada A, Bever N et al.. “Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.” Journal of neuro-oncology (2025). PMID: 40353934 ↗

    L2bCOHORTCited in: Immunohistochemistry and Molecular Markers
  118. [118]

    Song D, Wei Q, Zhao S et al.. “Exploring a recurrence model for atypical meningioma based on multiparametric MRI radiomic and clinical characteristics: a multicenter retrospective cohort study.” Radiation oncology (London, England) (2025). PMID: 40045333 ↗

    L2bCOHORTCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations
  119. [119]

    Hugh JC, Haddon LSJ, Githaka JM. “Dexamethasone Suppresses Already Low Estrogen Receptor Levels in Meningiomas.” International journal of molecular sciences (2026). PMID: 41898640 ↗

    L5REVIEW_NARRATIVECited in: Immunohistochemistry and Molecular Markers
  120. [120]

    Davoodi F, Babamohamadi Z, Khajavi M et al.. “A case of an attic lesion presenting with unilateral hearing loss, diagnosed as a meningioma: a case report and review of the literature.” Journal of medical case reports (2025). PMID: 41286999 ↗

    L4CASE_REPORTCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology
  121. [121]

    Nitturi V, Nouri SH, English C et al.. “PD-L1 positivity predicts a unique hyperaggressive tumor group within MenG C meningiomas.” JNCI cancer spectrum (2026). PMID: 41795833 ↗

    L5OTHERCited in: Immunohistochemistry and Molecular Markers, Prognosis and Recurrence Patterns
  122. [122]

    Abt V, Thomas C, Wagner A et al.. “Efficacy of azacitidine in meningiomas and explorative analyses of underlying molecular mechanisms.” Neurosurgical review (2026). PMID: 41577852 ↗

    L5OTHERCited in: Immunohistochemistry and Molecular Markers, Surgical Management and Techniques
  123. [123]

    Ma X, Zhao Y, Zhang K et al.. “Development of a predictive model for Ki-67 index of meningiomas by integrating deep-learning, radiomics and clinical features utilizing fully automated segmentation results.” Computer methods and programs in biomedicine (2026). PMID: 41418581 ↗

    L5OTHERCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology
  124. [124]

    Gao P, Wei J, Wang W et al.. “Brain-tumor interface-based MRI radiomics models to predict Ki-67 proliferation status of meningiomas: A multi-center study.” European journal of radiology (2026). PMID: 41325728 ↗

    L5OTHERCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns
  125. [125]

    Umekawa M, Shinya Y, Hirano Y et al.. “Molecular insights into prognostic model for meningiomas treated with stereotactic radiosurgery: negative impacts of 1q gain on tumor control and survival.” Acta neuropathologica communications (2025). PMID: 41239509 ↗

    L5OTHERCited in: Immunohistochemistry and Molecular Markers, Radiation Therapy and Radiosurgery, Special Populations: Pediatric and Genetic Syndromes
  126. [126]

    Ren L, Deng J, Xu J et al.. “SUV-max of 68Ga-DOTATATE PET/CT correlates with WHO grade and RNA risk classification in meningioma.” Journal of neuro-oncology (2025). PMID: 41129031 ↗

    L5OTHERCited in: Immunohistochemistry and Molecular Markers
  127. [127]

    Bekelman NJ, Ghaith AK, Yang L et al.. “Rates of recurrence and symptom improvement following resection of spinal meningiomas in the pediatric population: individual participant data meta-analysis.” Journal of neuro-oncology (2026). PMID: 41569438 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  128. [128]

    Pashkov A, Filimonova E, Poptsova A et al.. “Cognitive, affective and behavioral functioning in patients with olfactory groove meningiomas: a systematic review.” Neurosurgical review (2025). PMID: 40439793 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations
  129. [129]

    Courret T, Barreau X, Engelhardt J et al.. “Endovascular stenting for intracranial venous hypertension caused by meningioma: A case series and systematic literature review.” Journal of neuroradiology = Journal de neuroradiologie (2025). PMID: 40049399 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations
  130. [130]

    Tanti MJ, Nevitt S, Yeo M et al.. “Oedema as a prognostic factor for seizures in meningioma - a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 39969698 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations
  131. [131]

    Khan MF, Patel S, Alnasser AA et al.. “Predicting epilepsy in patients diagnosed with intracranial meningiomas: A systematic review and meta-analysis of clinical and anatomical risk factors.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40645150 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations
  132. [132]

    Putzler DH, Khan MF, Paulo FO et al.. “Intracranial meningioma with intratumoral hemorrhage: A systematic review of associated features and outcomes.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40090153 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations
  133. [133]

    Guerra P, Silva I, Araújo M et al.. “Xanthomatous Meningiomas: A Systematic Review and Case Report.” Turkish neurosurgery (2025). PMID: 41165380 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology
  134. [134]

    Ogura T, Fukuhara N, Yamaguchi-Okada M et al.. “Clinical features of intrasellar meningiomas treated with endoscopic endonasal surgery: a case series and comparison with other parasellar meningiomas and a literature review.” Neurosurgical review (2025). PMID: 40189713 ↗

    L4CASE_REPORTCited in: Clinical Presentation and Neurological Manifestations
  135. [135]

    Qin J, Li C, Fu J et al.. “Construction and application of a nomogram model for predicting postoperative cerebral edema in meningiomas based on radiomics and clinical features.” Acta radiologica (Stockholm, Sweden : 1987) (2025). PMID: 40474660 ↗

    L1bRCTCited in: Clinical Presentation and Neurological Manifestations
  136. [136]

    Cook WH, Gillespie CS, Bakhsh A et al.. “Epileptogenesis in meningioma: Theories, putative biomarkers, and postoperative risk.” Epilepsia (2025). PMID: 40729436 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Neurological Manifestations
  137. [137]

    Abdullaev AN, Dzhindzhikhadze RS, Polyakov AV et al.. “[Approaches in microsurgery for olfactory meningiomas: a systematic review and meta-analysis].” Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko (2026). PMID: 41930435 ↗

    L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations, Surgical Management and Techniques
  138. [138]

    Lin LC, Chow WH, Wu YJ et al.. “Salvage boron neutron capture therapy for recurrent intracranial malignant meningioma: Case report and literature review.” Medicine (2025). PMID: 40760503 ↗

    L4CASE_REPORTCited in: Clinical Presentation and Neurological Manifestations
  139. [139]

    Chang HF, Maimaitiaili N, Huo JF et al.. “Clinical and pathological characteristics of pulmonary meningioma: a case report and literature review.” The Journal of international medical research (2025). PMID: 39981620 ↗

    L4CASE_REPORTCited in: Clinical Presentation and Neurological Manifestations
  140. [140]

    Tolppola L, Pohjola A, Vasankari V et al.. “3D digital exoscope is safe tool in the surgery of olfactory groove meningiomas.” Acta neurochirurgica (2026). PMID: 41792536 ↗

    L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  141. [141]

    Basaran AE, Braune M, Barrantes-Freer A et al.. “FOXC1 expression and radiological predictors of peritumoral brain edema in meningiomas.” Journal of neuro-oncology (2026). PMID: 41632362 ↗

    L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns
  142. [142]

    Wang Z, Chen L, Li Y et al.. “Integrating diffusion-weighted MRI radiomics features to predict brain invasion of meningiomas.” Neurosurgical review (2025). PMID: 41354891 ↗

    L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns
  143. [143]

    Bin-Alamer O, Taori S, Abou-Al-Shaar H et al.. “Early outcomes of Gamma Knife stereotactic radiosurgery for symptomatic intracranial meningiomas in octogenarians: technique analysis and rationale.” Journal of neuro-oncology (2025). PMID: 41186800 ↗

    L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Radiation Therapy and Radiosurgery
  144. [144]

    Dallan I, Serioli S, de Notaris M et al.. “Transorbital management of selected spheno-orbital meningiomas: Insights from a multicentric retrospective Italian study of 52 cases.” Neurosurgical review (2025). PMID: 41081961 ↗

    L5OTHERCited in: Clinical Presentation and Neurological Manifestations
  145. [145]

    Sotera G, Forte C, D'Urso DG et al.. “In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.” International journal of molecular sciences (2025). PMID: 40943185 ↗

    L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Special Populations: Pediatric and Genetic Syndromes
  146. [146]

    Jacquesson T, Goichot L, Beaumont A et al.. “High-resolution T2-weighted MRI versus tractography to predict cranial nerve anatomy in skull base tumors: a retrospective 132-case series.” Journal of neurosurgery (2026). PMID: 41576385 ↗

    L4CASE_REPORTCited in: Diagnostic Imaging and Radiology
  147. [147]

    Kondo A, Umezawa H, Taga M et al.. “Salvage Reconstruction With Recycled Flap Pedicles in Head-and-Neck Surgery: A Report of Two Cases.” Microsurgery (2025). PMID: 41190748 ↗

    L4CASE_REPORTCited in: Diagnostic Imaging and Radiology, Surgical Management and Techniques
  148. [148]

    Khiralla A, Giotta Lucifero A, Al-Mefty O. “Median medullary perforators: Anatomical, surgical, and clinical significance in foramen magnum meningiomas.” Neurosurgical review (2025). PMID: 41099782 ↗

    L4CASE_REPORTCited in: Diagnostic Imaging and Radiology
  149. [149]

    Tatoğlu MT, Atalay B. “Incidental detection of anterior clinoid meningioma on [⁶⁸Ga]Ga-DOTATATE PET/CT in a patient with suspected neuroendocrine tumor.” Neuroradiology (2025). PMID: 41026227 ↗

    L4CASE_REPORTCited in: Diagnostic Imaging and Radiology
  150. [150]

    Coffee E, Elshiekh C, Budhu JA. “Imaging in Neuro-oncology.” Seminars in neurology (2025). PMID: 41082927 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Imaging and Radiology
  151. [151]

    Gao M, Zang H, Zhao W et al.. “Unraveling glymphatic disruption in brain tumors: Insights from perivascular space network analysis.” International journal of cancer (2026). PMID: 41795205 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology
  152. [152]

    Sadeghzadeh N, Correia JA, Shen J et al.. “A single MRI scan contains sufficient imaging information for accurate prediction of meningioma growth risk.” NeuroImage. Clinical (2026). PMID: 41780349 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology
  153. [153]

    Pineda-Ibarra C, Puig J, Nuñez-Leiva D et al.. “Brain MRI Radiomic First-Order Features for Presurgical Prediction of Meningioma Grading.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2026). PMID: 41635960 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  154. [154]

    Duarte Gomes M, Campos Cardoso HM, Coutinho R et al.. “Diagnostic Value of Routine MRI Parameters in Identifying High-Grade Intracranial Meningiomas.” Neuroradiology (2026). PMID: 41518389 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns
  155. [155]

    Kikuchi K, Togao O, Yamashita K et al.. “Relaxometry assessment of meningioma consistency using quantitative magnetic resonance imaging.” Neuroradiology (2026). PMID: 41457092 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology
  156. [156]

    Tan G, Feng Z, Xiao G et al.. “Machine learning based radiomics outperforms tumor/cerebellar peduncle T2-weighted imaging intensity ratios and ROIs-based apparent diffusion coefficient measurements in the preoperative prediction of meningioma consistency.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41406538 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns
  157. [157]

    Comeau MO, Gascon F, Corbeil M et al.. “Influence of dural attachment on remnant progression after subtotal resection in WHO grade 1 meningioma.” Acta neurochirurgica (2025). PMID: 41381949 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns
  158. [158]

    Garcia-Garcia S, Laajava J, Takala J et al.. “MRI radiomic signature predicts peritumoral brain edema resolution following meningioma surgery.” Acta neurochirurgica (2025). PMID: 41339597 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology
  159. [159]

    Turcas A, Bodensohn R, Clerici E et al.. “Patterns of care in primary brain tumour Reirradiation: A survey by the ESTRO CNS focus Group.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41290090 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology, Radiation Therapy and Radiosurgery, Guidelines and Resources
  160. [160]

    Bazani A, Bagnalasta M, Fontana G et al.. “Investigation of the combined role of dose and dose-averaged LET in the occurrence of brain necrosis after intensity modulated proton therapy for meningioma and solitary fibrous tumours.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41271170 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology, Radiation Therapy and Radiosurgery
  161. [161]

    Kaijser M, Feychting M, Skare S et al.. “The validity of the information on date of diagnosis of intracranial tumors in the Swedish cancer register.” European journal of epidemiology (2026). PMID: 41137898 ↗

    L5OTHERCited in: Diagnostic Imaging and Radiology
  162. [162]

    El-Abtah ME, Murayi R, Lee J et al.. “Radiological Differentiation Between Intracranial Meningioma and Solitary Fibrous Tumor/Hemangiopericytoma: A Systematic Literature Review.” World neurosurgery (2023). PMID: 36403933 ↗

    L2aSR_OBSCited in: Differential Diagnosis, Guidelines and Resources
  163. [163]

    Hicks WH, Pernik MN, Adeyemo E et al.. “Contiguous Meningioma and B-Cell Lymphoma: A Scoping Review and Case Illustration.” World neurosurgery (2022). PMID: 34798339 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  164. [164]

    Ashizawa K, Ogura K, Nagase S et al.. “A collision tumor of solitary fibrous tumor/hemangiopericytoma and meningioma: A case report with literature review.” Pathology international (2021). PMID: 34411369 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  165. [165]

    Beutler BD, Lee J, Edminster S et al.. “Intracranial meningioma: A review of recent and emerging data on the utility of preoperative imaging for management.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2024). PMID: 39113129 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  166. [166]

    Barden MM, Omuro AM. “Top advances of the year: Neuro-oncology.” Cancer (2023). PMID: 36825454 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  167. [167]

    Yamashita D, Suehiro S, Kohno S et al.. “Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis.” Neurosurgical review (2021). PMID: 32671693 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  168. [168]

    Helgager J, Driver J, Hoffman S et al.. “Molecular Advances in Central Nervous System Mesenchymal Tumors.” Surgical pathology clinics (2020). PMID: 32389268 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  169. [169]

    Glinka P, Sobstyl M, Rymkiewicz G et al.. “Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the dura mimicking meningioma: a case report and literature review.” Folia neuropathologica (2024). PMID: 38741437 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  170. [170]

    La Rocca G, Auricchio AM, Mazzucchi E et al.. “Intracranial dural based marginal zone MALT-type B-cell lymphoma: a case - Based update and literature review.” British journal of neurosurgery (2023). PMID: 34180316 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  171. [171]

    Engelhardt J, de Luzinais MG, Ollivier M et al.. “A case series of percutaneous transforamen ovale biopsies in cavernous sinus lesions.” Acta neurochirurgica (2022). PMID: 34136959 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  172. [172]

    Yang Z, Su X, Yuan Z et al.. “Mixed reality holographic navigation for intracranial lesions using HoloLens 2: A pilot study and literature review.” Clinical neurology and neurosurgery (2025). PMID: 40570755 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  173. [173]

    Horowitz T, Tabouret E, Graillon T et al.. “Contribution of nuclear medicine to the diagnosis and management of primary brain tumours.” Revue neurologique (2023). PMID: 36934021 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  174. [174]

    Park BJ, Dougherty MC, Noeller J et al.. “Spinal Meningioma in Adults: Imaging Characteristics, Surgical Outcomes, and Risk Factors for Recurrence.” World neurosurgery (2022). PMID: 35605940 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  175. [175]

    McNab AA, Jones RS, Hardy TG. “Spheno-orbital Lesions-A Major Review of Nonmeningioma Causes.” Ophthalmic plastic and reconstructive surgery (Unknown). PMID: 33782321 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  176. [176]

    Munawar K, Nayak G, Fatterpekar GM et al.. “Cavernous sinus lesions.” Clinical imaging (2020). PMID: 32574933 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  177. [177]

    Garg S, Gude G, Chatterjee D et al.. “Primary Dural Acute Lymphoblastic Leukaemia/Lymphoma Masquerading Meningioma: Report of a Case and Review of Literature.” Neurology India (2023). PMID: 37929440 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  178. [178]

    Ren L, Deng J, Feng A et al.. “Long-term follow-up outcomes in intracranial solitary fibrous tumor compared with meningioma: a propensity score matching study.” Journal of neurosurgery (2025). PMID: 40882230 ↗

    L5OTHERCited in: Differential Diagnosis
  179. [179]

    Kaley TJ, Grommes C, Coffee E et al.. “Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma.” Neuro-oncology (2025). PMID: 40842355 ↗

    L5OTHERCited in: Differential Diagnosis
  180. [180]

    Toth LF, Majós C, Pons-Escoda A et al.. “Machine Learning Analysis of Single-Voxel Proton MR Spectroscopy for Differentiating Solitary Fibrous Tumors and Meningiomas.” NMR in biomedicine (2025). PMID: 40186532 ↗

    L5OTHERCited in: Differential Diagnosis
  181. [181]

    Fiorante A, Woolman M, Munoz DG et al.. “A molecular array for 10-second diagnosis of common spinal tumor types with picosecond infrared laser mass spectrometry.” Neuro-oncology (2025). PMID: 39980445 ↗

    L5OTHERCited in: Differential Diagnosis
  182. [182]

    Mirchia K, Choudhury A, Joseph T et al.. “Meningeal solitary fibrous tumor cell states phenocopy cerebral vascular development and homeostasis.” Neuro-oncology (2025). PMID: 39207122 ↗

    L5OTHERCited in: Differential Diagnosis
  183. [183]

    Zhang L, Li C, Marhaba Aziz et al.. “ITF2357 induces cell cycle arrest and apoptosis of meningioma cells via the PI3K-Akt pathway.” Medical oncology (Northwood, London, England) (2022). PMID: 36445551 ↗

    L5OTHERCited in: Differential Diagnosis
  184. [184]

    Aunan-Diop JS, Andersen MCS, Friismose AI et al.. “Virtual magnetic resonance elastography predicts the intraoperative consistency of meningiomas.” Journal of neuroradiology = Journal de neuroradiologie (2023). PMID: 36343849 ↗

    L5OTHERCited in: Differential Diagnosis
  185. [185]

    Liu X, Deng J, Sun Q et al.. “Differentiation of intracranial solitary fibrous tumor/hemangiopericytoma from atypical meningioma using apparent diffusion coefficient histogram analysis.” Neurosurgical review (2022). PMID: 35303202 ↗

    L5OTHERCited in: Differential Diagnosis
  186. [186]

    Marletta S, Luchini C, Sperandio N et al.. “CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.” Virchows Archiv : an international journal of pathology (2022). PMID: 35212813 ↗

    L5OTHERCited in: Differential Diagnosis
  187. [187]

    Sloan EA, Gupta R, Koelsche C et al.. “Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas.” Brain pathology (Zurich, Switzerland) (2022). PMID: 34821426 ↗

    L5OTHERCited in: Differential Diagnosis
  188. [188]

    Apra C, Guillemot D, Frouin E et al.. “Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities.” Journal of neuro-oncology (2021). PMID: 34417711 ↗

    L5OTHERCited in: Differential Diagnosis
  189. [189]

    Nagai Yamaki V, de Souza Godoy LF, Alencar Bandeira G et al.. “Dural-based lesions: is it a meningioma?” Neuroradiology (2021). PMID: 33459822 ↗

    L5OTHERCited in: Differential Diagnosis
  190. [190]

    Yoo J, Park HH, Yun IS et al.. “Clinical applications of the endoscopic transorbital approach for various lesions.” Acta neurochirurgica (2021). PMID: 33394139 ↗

    L5OTHERCited in: Differential Diagnosis
  191. [191]

    Hong J, Moes G, Lai J. “Intraoperative Frozen Section Diagnosis of Brain Rosai-Dorfman Disease Clinically and Radiologically Mimicking Meningioma.” In vivo (Athens, Greece) (2025). PMID: 41167660 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  192. [192]

    Arnautovic KI, Lasica N. “Update on anterior clinoid process removal in anterior clinoid meningioma surgery: literature review, and a new didactical concept.” Acta neurochirurgica (2025). PMID: 41432809 ↗

    L2aSR_OBSCited in: Surgical Management and Techniques
  193. [193]

    Feng QJ, Zheng Y, Cheong TKF et al.. “Revisiting traditional transcranial approaches for anterior skull base meningiomas: a systematic review and meta-analysis of transcranial approaches against minimally invasive surgical techniques.” Neurosurgical review (2025). PMID: 41388197 ↗

    L2aSR_OBSCited in: Surgical Management and Techniques, Prognosis and Recurrence Patterns
  194. [194]

    Sivanathan S, Al-Rabadi J, Alexander KG et al.. “Endoscopic Endonasal Approach for Primary Optic Nerve Sheath Meningioma: A Systematic Review.” World neurosurgery (2026). PMID: 41570978 ↗

    L2aSR_OBSCited in: Surgical Management and Techniques, Prognosis and Recurrence Patterns
  195. [195]

    Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Efficacy and Safety of Stereotactic Radiosurgery for Cerebellopontine Angle Meningiomas: A Systematic Review and Meta-Analysis.” Neuro-Chirurgie (2026). PMID: 41397526 ↗

    L2aSR_OBSCited in: Surgical Management and Techniques, Radiation Therapy and Radiosurgery, Prognosis and Recurrence Patterns
  196. [196]

    Quintin K, Josset S, Latorzeff I et al.. “Radiotherapy of benign intracranial tumours: 2025 update.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41273886 ↗

    L1cGUIDELINECited in: Surgical Management and Techniques, Radiation Therapy and Radiosurgery, Guidelines and Resources
  197. [197]

    Abdelgadir J, Nadel J, Zachem TJ et al.. “Deciding when and when not to reconstruct the orbit: How I do it.” Acta neurochirurgica (2026). PMID: 41691074 ↗

    L4CASE_REPORTCited in: Surgical Management and Techniques
  198. [198]

    Al-Hamid S, Grellmann F, Reiser J et al.. “Combining 3D printing and elastographic characterization: A novel sphenoid wing meningioma simulation model for neurosurgical training.” Neurosurgical review (2026). PMID: 41535607 ↗

    L5OTHERCited in: Surgical Management and Techniques
  199. [199]

    Sakaeyama Y, Kubota S, Abe M et al.. “Usefulness of a 3 Dimensional-printed Head Model with Two-layered Dura and Cerebellar Tentorium for Transpetrosal Approach Training.” Neurologia medico-chirurgica (2026). PMID: 41526252 ↗

    L5OTHERCited in: Surgical Management and Techniques
  200. [200]

    Yamashiro K, Kozaki T, Fukumoto H et al.. “Risk assessment of brain retraction injury based on quantitative evaluation of brain retraction distance during skull-base meningioma surgery.” Neurosurgical review (2026). PMID: 41489755 ↗

    L5OTHERCited in: Surgical Management and Techniques
  201. [201]

    Fariselli L, Marzoli SB, Morlino S et al.. “Hypofractionated Radiosurgery (25 Gy/5 Fractions) for Optic Nerve Sheath Meningiomas: Results From an Exploratory Phase 2 Prospective Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40349855 ↗

    L2bTRIAL_NONRANDOMCited in: Radiation Therapy and Radiosurgery
  202. [202]

    Perlow HK, Raleigh DR, Wang TJC et al.. “Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas.” International journal of radiation oncology, biology, physics (2025). PMID: 39701546 ↗

    L1cGUIDELINECited in: Radiation Therapy and Radiosurgery, Guidelines and Resources
  203. [203]

    Gomes FC, Larcipretti ALL, Mariano ÍGGF et al.. “GammaKnife radiosurgery for meningiomas in neurofibromatosis type II patients: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 40237947 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery, Special Populations: Pediatric and Genetic Syndromes
  204. [204]

    Cook WH, Khalil F, Gillespie CS et al.. “Health-related quality-of-life outcomes in CNS WHO grade 2 and 3 meningioma: a systematic review.” Neurosurgical review (2025). PMID: 40011234 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  205. [205]

    Habibi MA, Mirjani MS, Ahmadvand MH et al.. “Gamma knife stereotactic radiosurgery for neurofibromatosis 2 (NF2)-associated meningiomas; a systematic review and meta-analysis.” Acta neurochirurgica (2025). PMID: 39907804 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery, Special Populations: Pediatric and Genetic Syndromes
  206. [206]

    Javadnia P, Bahadori AR, Ghanaatpisheh A et al.. “The safety and efficacy of robotic radiosurgery and radiotherapy in the management of skull base tumors: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 39792270 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  207. [207]

    Lesueur P, Clarisse B, Lequesne J et al.. “Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).” BMC cancer (2024). PMID: 39736544 ↗

    L2bTRIAL_NONRANDOMCited in: Radiation Therapy and Radiosurgery
  208. [208]

    Hajikarimloo B, Tos SM, Habibi MA et al.. “Efficacy and safety of stereotactic radiosurgery for foramen magnum meningiomas: a systematic review and meta-analysis.” Journal of neurosurgical sciences (2025). PMID: 40662245 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  209. [209]

    Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Stereotactic radiosurgery for optic nerve sheath meningiomas: A comprehensive systematic review and meta-analysis.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40580760 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  210. [210]

    Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Efficacy and safety of stereotactic radiosurgery for large meningiomas: A comprehensive systematic review and meta-analysis.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40505253 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  211. [211]

    Hajikarimloo B, Mohammadzadeh I, Tos SM et al.. “Stereotactic radiosurgery for tumor-related trigeminal neuralgia: a systematic review and meta-analysis.” BMC neurology (2025). PMID: 40319265 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  212. [212]

    Chow A, Hovis GEA, Ghodrati F et al.. “Early-onset stroke-like migraine attacks after radiation therapy syndrome: A case report and review of the literature.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 39675213 ↗

    L2aSR_OBSCited in: Radiation Therapy and Radiosurgery
  213. [213]

    Kumar R, Carlstrom LP, Morshed R et al.. “Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study.” Neurosurgery (2025). PMID: 40476726 ↗

    L2bCOHORTCited in: Radiation Therapy and Radiosurgery
  214. [214]

    Nguyen BT, Huynh CT, Nguyen TM et al.. “Gamma knife radiosurgery for benign tumor-related trigeminal neuralgia: a single-institution retrospective study.” Neurosurgical review (2025). PMID: 39960553 ↗

    L2bCOHORTCited in: Radiation Therapy and Radiosurgery
  215. [215]

    Lesueur P, Joly F, Clarisse B et al.. “Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG).” Radiation oncology (London, England) (2025). PMID: 39881369 ↗

    L2bCOHORTCited in: Radiation Therapy and Radiosurgery
  216. [216]

    Hotsinpiller WS, Thomas EM, Tsekouras I et al.. “Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity.” Journal of neuro-oncology (2025). PMID: 41118008 ↗

    L5OTHERCited in: Radiation Therapy and Radiosurgery
  217. [217]

    Alhosanie TN, Hammo B, Klaib AF et al.. “Integrating artificial intelligence with Gamma Knife radiosurgery in treating meningiomas and schwannomas: a review.” Neurosurgical review (2025). PMID: 40965768 ↗

    L5REVIEW_NARRATIVECited in: Radiation Therapy and Radiosurgery
  218. [218]

    Wang Y, Wang C, Yin S et al.. “Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.” CNS neuroscience & therapeutics (2025). PMID: 41358608 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments, Prognosis and Recurrence Patterns
  219. [219]

    Nakhate V, Ly I, Muzikansky A et al.. “Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.” Journal of neuro-oncology (2025). PMID: 40434540 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments, Special Populations: Pediatric and Genetic Syndromes
  220. [220]

    Abikenari M, Regev A, Himic V et al.. “The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.” Journal of neuro-oncology (2025). PMID: 40392516 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments
  221. [221]

    Kotecha R, Akdemir EY, Kutuk T et al.. “Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.” Neuro-oncology (2025). PMID: 39807850 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments
  222. [222]

    Dijkstra BM, Cordia QCF, Nonnekens J et al.. “Bevacizumab-IRDye800CW for tumor detection in fluorescence-guided meningioma surgery (LUMINA trial): a single-center phase I study.” Journal of neurosurgery (2024). PMID: 38968617 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments
  223. [223]

    Deng MY, Maas SLN, Hinz F et al.. “Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.” Neuro-oncology (2024). PMID: 38079455 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments
  224. [224]

    Bosio A, Cerretti G, Padovan M et al.. “Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).” Trials (2025). PMID: 40759981 ↗

    L1bRCTCited in: Systemic Therapy and Emerging Treatments
  225. [225]

    Jensen LR, Maier AD, Juratli TA et al.. “The concept, intention, and evaluation of the term treatment-refractory meningioma.” Journal of neuro-oncology (2025). PMID: 40760312 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments
  226. [226]

    Hajikarimloo B, Hasanzade A, Sabbagh Alvani M et al.. “Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.” Neurosurgical review (2024). PMID: 39327340 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments
  227. [227]

    Watanabe G, Young K, Rauber E et al.. “A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.” Journal of neuro-oncology (2024). PMID: 38530549 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments
  228. [228]

    Casey DL, Vogelius IR, Brodin NP et al.. “Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review.” International journal of radiation oncology, biology, physics (2024). PMID: 37777927 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments
  229. [229]

    Himič V, Burman RJ, Fountain DM et al.. “Metastatic meningioma: a case series and systematic review.” Acta neurochirurgica (2023). PMID: 37491650 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments, Guidelines and Resources
  230. [230]

    Kaye J, Na J, Atluri S et al.. “Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review.” World neurosurgery (2024). PMID: 38901486 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments
  231. [231]

    Boursier C, Zaragori T, Imbert L et al.. “177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review.” The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... (2024). PMID: 39026463 ↗

    L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments
  232. [232]

    Galluzzo D, Chen C, Alok K et al.. “Evolving Treatment Paradigms of Meningiomas; a Precision Medicine Perspective.” Current neurology and neuroscience reports (2025). PMID: 41085787 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  233. [233]

    Yamazawa E, Sullivan E, Wakimoto H et al.. “Emerging targeted therapies in meningiomas.” Current opinion in neurology (2025). PMID: 41069194 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  234. [234]

    Quach S, Simon M. “Diagnostic advances and challenges in meningioma.” Expert review of neurotherapeutics (2025). PMID: 40826833 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  235. [235]

    Albert NL, Tabouret E, Le Rhun E et al.. “[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial.” Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2026). PMID: 40774695 ↗

    L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments
  236. [236]

    Kooi EJ, Marcelis L, Wesseling P. “Pathological diagnosis of central nervous system tumours in adults: what's new?” Pathology (2025). PMID: 39818455 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  237. [237]

    Pereira BJA, de Almeida AN, Paiva WS et al.. “Impact on natural history of atypical meningioma after changes in 2016 edition of the world health organization (WHO) classification of central nervous system tumors: a literature review.” Neurosurgical review (2024). PMID: 39340638 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  238. [238]

    Pourhadi N, Meaidi A, Friis S et al.. “Menopausal hormone therapy and central nervous system tumors: Danish nested case-control study.” PLoS medicine (2023). PMID: 38113227 ↗

    L3bCASE_CONTROLCited in: Systemic Therapy and Emerging Treatments
  239. [239]

    Li Y, Drappatz J. “Advances in the systemic therapy for recurrent meningiomas and the challenges ahead.” Expert review of neurotherapeutics (2023). PMID: 37695700 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  240. [240]

    Tamura R. “Drug Repositioning for Refractory Benign Tumors of the Central Nervous System.” International journal of molecular sciences (2023). PMID: 37629179 ↗

    L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments
  241. [241]

    Nguyen DC, Nader C, Bélanger K et al.. “A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.” Current oncology (Toronto, Ont.) (2025). PMID: 41002586 ↗

    L2bCOHORTCited in: Systemic Therapy and Emerging Treatments
  242. [242]

    Fukumura M, Kashiwagi H, Yoshimura K et al.. “Perfusion changes associated with intratumoral embolization and feeder occlusion for meningiomas: an arterial spin labeling study.” Acta neurochirurgica (2026). PMID: 41673213 ↗

    L5OTHERCited in: Prognosis and Recurrence Patterns
  243. [243]

    Duckett D, Santana-Santos L, McCord M et al.. “Development, validation, and utility of a clinically applicable methylation classifier for recurrence risk prediction in meningiomas.” Acta neuropathologica communications (2025). PMID: 41466325 ↗

    L5OTHERCited in: Prognosis and Recurrence Patterns
  244. [244]

    Zhu Y, Rudolf MA, Conway K et al.. “A practical approach for assessing high-grade diffuse gliomas and meningiomas.” Human pathology (2026). PMID: 41419116 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Recurrence Patterns
  245. [245]

    Wach J, Vychopen M, Basaran AE et al.. “Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis.” Journal of neuro-oncology (2025). PMID: 39779595 ↗

    L2aSR_OBSCited in: Special Populations: Pediatric and Genetic Syndromes
  246. [246]

    Zuniga RDDR, Carrijo GS, do Vale MR et al.. “Pathogenic Variants and Prognosis in Meningiomas: A Systematic Review and Meta-Analysis.” World neurosurgery (2025). PMID: 40254182 ↗

    L2aSR_OBSCited in: Special Populations: Pediatric and Genetic Syndromes
  247. [247]

    Nobee A, Xu M, Seth A et al.. “Atypical Intraparenchymal Meningioma with YAP1-MAML2 Fusion in a Young Adult Male: A Case Report and Mini Literature Review.” International journal of molecular sciences (2023). PMID: 37628996 ↗

    L4CASE_REPORTCited in: Special Populations: Pediatric and Genetic Syndromes
  248. [248]

    Sahm F, Aldape KD, Brastianos PK et al.. “cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.” Neuro-oncology (2025). PMID: 39212325 ↗

    L5REVIEW_NARRATIVECited in: Special Populations: Pediatric and Genetic Syndromes
  249. [249]

    Grilli F, Smaili HY, Bianchi F et al.. “Hyperostotic meningiomas in children. A case-based update.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2024). PMID: 39661177 ↗

    L4CASE_REPORTCited in: Special Populations: Pediatric and Genetic Syndromes
  250. [250]

    Kalamarides M, Pathmanaban O, Peyre M et al.. “Surgery in NF2-Schwannomatosis.” Familial cancer (2025). PMID: 41420725 ↗

    L5REVIEW_NARRATIVECited in: Special Populations: Pediatric and Genetic Syndromes
  251. [251]

    Gregory GE, Haley MJ, Jones AP et al.. “The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.” Acta neuropathologica communications (2025). PMID: 41437121 ↗

    L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes
  252. [252]

    Chang LS, Oblinger JL, Wu LMN et al.. “Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas.” Cancer research communications (2026). PMID: 41417846 ↗

    L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes
  253. [253]

    Deboeuf L, Keraudy A, Picart T et al.. “Prevalence, natural history and surgical outcome of spinal meningiomas in NF2-related schwannomatosis.” Journal of neuro-oncology (2025). PMID: 40958044 ↗

    L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes
  254. [254]

    Hirano Y, Miyawaki S, Sakai Y et al.. “Integrated molecular and detailed anatomical profiling identifies a prognostically adverse subtype of posterior fossa meningiomas: high-risk copy number alterations are associated with midline predilection and predict poor prognosis.” Acta neuropathologica communications (2025). PMID: 40775657 ↗

    L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes
  255. [255]

    Koçyiğit S, Chavez MM, Orhun Ö et al.. “Posterior parasagittal meningiomas display aggressive features independent of size: a multicenter analysis.” Journal of neuro-oncology (2025). PMID: 40569492 ↗

    L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes
  256. [256]

    Fan H, Li X, Zhao Y et al.. “Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies.” Journal of neuro-oncology (2025). PMID: 40522564 ↗

    L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes
  257. [257]

    Albert NL, Preusser M, Traub-Weidinger T et al.. “Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.” European journal of nuclear medicine and molecular imaging (2024). PMID: 38898354 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  258. [258]

    Martz N, Salleron J, Dhermain F et al.. “Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.” Radiation oncology (London, England) (2023). PMID: 37408055 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  259. [259]

    Goldbrunner R, Stavrinou P, Jenkinson MD et al.. “EANO guideline on the diagnosis and management of meningiomas.” Neuro-oncology (2021). PMID: 34181733 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  260. [260]

    Marchetti M, Sahgal A, De Salles AAF et al.. “Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline.” Neurosurgery (2020). PMID: 32463867 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  261. [261]

    Dissaux G, Josset S, Thillays F et al.. “Radiotherapy of benign intracranial tumours.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2022). PMID: 34953692 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  262. [262]

    Aziz HF, Bakhshi SK, Tariq R et al.. “Consensus guidelines for the management of primary supra-tentorial intraventricular tumour for low- and middle-income countries.” JPMA. The Journal of the Pakistan Medical Association (2024). PMID: 39262081 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  263. [263]

    Enam SA, Masroor M, Bakhshi SK et al.. “Consensus guidelines for the management of intracranial meningioma for low- and middle-income countries.” JPMA. The Journal of the Pakistan Medical Association (2024). PMID: 39262076 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  264. [264]

    Khaboushan AS, Ohadi MAD, Amani H et al.. “Stereotactic radiosurgery for intraventricular meningioma: a systematic review and meta-analysis.” Acta neurochirurgica (2024). PMID: 38980438 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  265. [265]

    Fouda MA, Kallman S, Boorstin R et al.. “The unseen impact - a deep dive into neurocognitive impairment among patients with intracranial meningiomas: a comprehensive systematic review of the literature.” Neurosurgical review (2024). PMID: 38922363 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  266. [266]

    Hallak H, Rindler R, Dang D et al.. “Trigeminal neuralgia pain outcomes following microsurgical resection versus stereotactic radiosurgery for petroclival meningiomas: a systematic review and meta-analysis.” Journal of neurosurgery (2024). PMID: 37542438 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  267. [267]

    Watanabe S, Nonaka T, Maeda M et al.. “Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials.” Therapeutic innovation & regulatory science (2023). PMID: 36602756 ↗

    L2bTRIAL_NONRANDOMCited in: Guidelines and Resources
  268. [268]

    Chen L, Li DH, Lu YH et al.. “Preoperative Embolization Versus Direct Surgery of Meningiomas: A Meta-Analysis.” World neurosurgery (2019). PMID: 30954743 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  269. [269]

    Vassantachart AK, Ehret F, Chen E et al.. “A Case-based Guide for World Health Organization (WHO) Grade 2 Meningioma Radiosurgery and Radiation Therapy from The Radiosurgery Society.” Practical radiation oncology (2024). PMID: 38970567 ↗

    L4CASE_REPORTCited in: Guidelines and Resources
  270. [270]

    Wang C, Chen Y, Zhang L et al.. “Thoracic psammomatous meningioma with osseous metaplasia: a controversial diagnosis of a case report and literature review.” World journal of surgical oncology (2019). PMID: 31445511 ↗

    L4CASE_REPORTCited in: Guidelines and Resources
  271. [271]

    Fuchs F, Marschner SN, Hofmaier J et al.. “SSTR PET/CT for skull base low-grade meningioma: a critical tool for accurate gross tumor volume delineation in radiotherapy?” Radiation oncology (London, England) (2025). PMID: 40983935 ↗

    L5OTHERCited in: Guidelines and Resources
  272. [272]

    Landry AP, Wang JZ, Yefet LS et al.. “Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies.” Neuro-oncology (2025). PMID: 39851181 ↗

    L5OTHERCited in: Guidelines and Resources
  273. [273]

    Sadashiva N, Goyal-Honavar A, Nadeem M et al.. “Surgical outcomes of trigonal intraventricular meningiomas: a single-centre study.” Neurosurgical review (2024). PMID: 38965148 ↗

    L5OTHERCited in: Guidelines and Resources
  274. [274]

    Wang JZ, Landry AP, Raleigh DR et al.. “Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.” Neuro-oncology (2024). PMID: 38695575 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  275. [275]

    Gu H, Yang C, Al-Kharouf I et al.. “Enhancing mitosis quantification and detection in meningiomas with computational digital pathology.” Acta neuropathologica communications (2024). PMID: 38212848 ↗

    L5OTHERCited in: Guidelines and Resources
  276. [276]

    Chen C, Teng Y, Tan S et al.. “Performance Test of a Well-Trained Model for Meningioma Segmentation in Health Care Centers: Secondary Analysis Based on Four Retrospective Multicenter Data Sets.” Journal of medical Internet research (2023). PMID: 38100181 ↗

    L5OTHERCited in: Guidelines and Resources
  277. [277]

    Bove I, Cheok S, Ruzevick JJ et al.. “Endoscopic Endonasal and Keyhole Surgery for Skull Base Meningiomas.” Neurosurgery clinics of North America (2023). PMID: 37210128 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  278. [278]

    Clynch AL, Norrington M, Mustafa MA et al.. “Cranial meningioma with bone involvement: surgical strategies and clinical considerations.” Acta neurochirurgica (2023). PMID: 36877330 ↗

    L5OTHERCited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…